BIOAGE LABS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIOAGE LABS, INC. (BIOA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.27M, a 32.21% increase year-over-year.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.26M, a 44.32% increase year-over-year.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.79M, a 51.03% increase year-over-year.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.23M, a 107.25% increase year-over-year.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.69M, a 67.52% increase from fiscal 2024.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.98M, a 131.40% increase from fiscal 2023.
- BIOAGE LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.02M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.27M 10-Q · filed 2026-08-05 | $8.53M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $4.26M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $11.69M 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $2.79M 10-Q · filed 2025-11-06 | $6.02M derived: sum of 2 quarters · filed 2026-08-05 | $8.97M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $3.23M 10-Q · filed 2026-08-05 | $6.18M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $2.95M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $6.98M 10-K · filed 2026-03-24 | |||
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-06 | $3.41M derived: sum of 2 quarters · filed 2025-11-06 | $4.26M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $1.56M 10-Q · filed 2025-11-06 | $2.41M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $852.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $3.02M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $757.00K 10-Q · filed 2024-11-07 | $1.51M derived: sum of 2 quarters · filed 2024-11-07 | $2.25M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $758.00K 10-Q · filed 2024-11-07 | $1.49M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $734.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |